rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2006-10-16
|
pubmed:abstractText |
Trastuzumab is the cornerstone for treatment of women with HER2-overexpressing breast cancer, both in the adjuvant and in the metastatic settings. The accurate assessment of HER2 is, therefore, critical to identifying patients who may benefit from trastuzumab-based therapy. This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1535-7163
|
pubmed:author |
pubmed-author:Dal LagoLissandraL,
pubmed-author:DesmedtChristineC,
pubmed-author:Di LeoAngeloA,
pubmed-author:DurbecqVirginieV,
pubmed-author:LarsimontDenisD,
pubmed-author:LespagnardLaurenceL,
pubmed-author:PiccartMartineM,
pubmed-author:SalgadoRobertoR,
pubmed-author:SotiriouChristosC,
pubmed-author:VerjatThibaultT,
pubmed-author:VeysIsabelleI,
pubmed-author:WinNN
|
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2572-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17041102-Aneuploidy,
pubmed-meshheading:17041102-Breast Neoplasms,
pubmed-meshheading:17041102-Chromosomes, Human, Pair 17,
pubmed-meshheading:17041102-Female,
pubmed-meshheading:17041102-Humans,
pubmed-meshheading:17041102-In Situ Hybridization, Fluorescence,
pubmed-meshheading:17041102-Nucleic Acid Amplification Techniques,
pubmed-meshheading:17041102-RNA, Messenger,
pubmed-meshheading:17041102-Receptor, erbB-2
|
pubmed:year |
2006
|
pubmed:articleTitle |
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
|
pubmed:affiliation |
Translational Research Unit, Bordet Institute, Brussels, Belgium.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|